Patents Examined by Meera Natarajan
  • Patent number: 11713351
    Abstract: The present invention relates to methods for preventing or treating head and neck squamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: August 1, 2023
    Assignee: University of Zürich
    Inventors: Uwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
  • Patent number: 11713352
    Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: August 1, 2023
    Assignee: University of Zürich
    Inventors: Uwe Zangemeister-Wittke, Claudio Di Paolo, Dominique Christine Tschudi, Nicholas Ronald Glover, Dimitri Peter Fitsialos
  • Patent number: 11697681
    Abstract: The present invention relates to an antigen-binding protein, or an antigen-binding fragment thereof, comprising (i) a heavy chain variable domain comprising a VHCDR1 having the amino acid sequence GYSITSGYSWH; a VHCDR2 having the amino acid sequence YIHYSGSTKYNPSLKS and a VHCDR3 having the amino acid sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 having the amino acid sequence KSSQSLLYSNDQKNYLA, a VLCDR2 having the amino acid sequence WASIRES, and a VLCDR3 having the amino acid sequence QQYYIYPLT.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: July 11, 2023
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Simeon Cua, Andre Boon Hwa Choo, Heng Liang Tan, Wey Jia Fong, Vanessa Mei Yee Ding, Leonard Wen Yan Leong
  • Patent number: 11685777
    Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: June 27, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ricardo Attar, Francois Gaudet, Mark Tornetta, Alexey Teplyakov, Mark Mendonca, Suzanne Edavettal, Kodandaram Pillarisetti, Nathan Majewski, Yingzhe Li, Leopoldo L. Luistro, III, Diana Chin
  • Patent number: 11679161
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: June 20, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Patent number: 11673945
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Patent number: 11673959
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first antibody region, a first therapeutic agent, and a first connecting peptide; wherein the first therapeutic agent is attached to the first antibody region by the connecting peptide; and wherein the connecting peptide does not comprise a region having beta strand secondary structure. The connecting peptide may comprise an extender peptide. The extender peptide may have an alpha helical secondary structure. The connecting peptide may comprise a linker peptide. The linker peptide may not comprise any secondary structure. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: June 13, 2023
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Feng Wang, Yong Zhang, Yan Liu, Peter G. Schultz
  • Patent number: 11655290
    Abstract: The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: May 23, 2023
    Assignee: Atreca, Inc.
    Inventors: Daniel Eric Emerling, Randal R. Ketchem, Shaun M. Lippow, Wayne Volkmuth, Katherine L. Williams
  • Patent number: 11643691
    Abstract: The present disclosure provides methods of detecting a wnt-?-catenin-mediated cancer and an immunotherapy resistant cancer by detecting the presence of an associated biomarker. Further, methods of threating the wnt-?-catenin-mediated cancer or immunotherapy resistant cancer are provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: May 9, 2023
    Assignee: Duke University
    Inventors: Brent Hanks, Nicholas Devito, Balamayooran Theivanthiran, Fei Zhao
  • Patent number: 11638761
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: May 2, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Patent number: 11629186
    Abstract: Anti-CCL8 antibodies and antigen binding fragments thereof are described. Antibodies and fragments thereof can be used for prevention of migration of breast cancer cells. Methods include delivery of an anti-CCL8 antibody or an antigen binding fragment thereof to an area including the breast cancer cells, e.g., delivery to a subject in need thereof in an effective amount.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: April 18, 2023
    Assignee: University of South Carolina
    Inventors: Hippokratis Kiaris, Eleni Farmaki, Ioulia Chatzistamou, Vimala Kaza
  • Patent number: 11608375
    Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: March 21, 2023
    Assignee: MedImmune, LLC
    Inventors: Nabendu Pore, Martin J. Borrok, III, Emil F. Michelotti, David A. Tice, Robert E. Hollingsworth, Chien-Ying Chang, Partha Chowdhury
  • Patent number: 11572412
    Abstract: The present invention relates to anti-SIRP? (Signal regulatory protein alpha) antibodies and antigen-binding fragments thereof for therapeutic and diagnostic methods and compositions using them.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: February 7, 2023
    Assignees: Boehringer Ingelheim International GmbH, OSE Immmnotherapeatics SA
    Inventors: Pankaj Gupta, Priyanka Gupta, Habte Habtom, Yining Huang, Sandeep Kumar, Kathryn Phoenix, Kerry-Leigh Ralph, Wing Pan Kenny Tsang, Eduardo Sergio Trombetta
  • Patent number: 11572410
    Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: February 7, 2023
    Assignee: INNATE PHARMA
    Inventors: Pascale Andre, Mathieu Blery, Carine Paturel, Nicolai Wagtmann
  • Patent number: 11525012
    Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 13, 2022
    Assignee: MedImmune Limited
    Inventors: Carl Hay, Kris Sachsenmeier, Erin Sult, Qihui Huang, Peter Pavlik, Melissa Damschroder, Li Cheng, Gundo Diedrich, Jonathan Rios-Doria, Scott Hammond, Ralph Minter, Steve Rust, Sandrine Guillard, Robert Hollingsworth, Lutz Jermutus, Nicholas Durham, Ching Ching Leow, Mary Antonysamy, James Geoghegan, Xiaojun Lu, Kim Rosenthal
  • Patent number: 11518813
    Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: December 6, 2022
    Assignee: GENSUN BIOPHARMA, INC.
    Inventors: Jackie Sheng, Bo Liu
  • Patent number: 11505604
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 22, 2022
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Patent number: 11505602
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 22, 2022
    Assignee: PIONYR IMMUNOTHERAPEUTICS, INC.
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Patent number: 11492414
    Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 8, 2022
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
  • Patent number: 11485783
    Abstract: Provided are antibodies or fragment thereof having binding specificity to the human GPRC5D protein. The antibodies or fragment thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: November 1, 2022
    Assignee: LANOVA MEDICINES DEVELOPMENT CO., LTD.
    Inventors: Runsheng Li, Wentao Huang